Combined intraarterial and intravenous thrombolysis for severe cerebral venous sinus thrombosis.
To investigate the safety and efficacy of endovascular therapy with combined intra-arterial and intravenous thrombolysis for severe cerebral venous sinus thrombosis. Of the 28 consecutive patients with cerebral venous sinus thrombosis admitted to our hospital in recent 3 years, six patients underwent combined intra-arterial and intravenous thrombolysis. For each patient, local contact thrombolysis was performed with balloon catheter to break clot and urokinase infused for thrombolysis in sinus. At the same time, urokinase (100,000 IU/h) was infused intra-arterially via internal carotid artery to dissolve the venous thrombi. Neurologic outcomes, Glasgow coma scale (GCS), neuroimaging results and modified Rankin Scale score (mRS) were recorded. Of the six treated patients, two were males and four females. Their mean age was 38 +/- 13 (range from 22 to 57) years. Completely recanalization was observed in five patients, whose clinical symptoms recovered completely (mRS score 0). One patient in whom thrombolysis was delayed died the day after the procedure. Endovascular treatment with combined intra-arterial and intravenous thrombolysis may improve neurological outcomes of severe cerebral venous sinus thrombosis.
Yue
Xuanye
X
Department of Neurology, Jinling Hospital, Nanjing University School of Medicine, 305# East Zhongshan Road, 210002, Nanjing, Jiangsu Province, People's Republic of China.
Xi
Gangming
G
Zhou
Zhiming
Z
Xu
Gelin
G
Liu
Xinfeng
X
D000328:Adult; D002404:Catheterization / Q000379:methods; D003131:Combined Modality Therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011859:Radiography; D012189:Retrospective Studies; D012720:Severity of Illness Index; D012851:Sinus Thrombosis, Intracranial / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000628:therapy; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage; D055815:Young Adult
D005343:Fibrinolytic Agents; D014568:Urokinase-Type Plasminogen Activator
J R Soc Med. 2000 May;93(5):241-3
10884767
J Neurol. 2004 Jan;251(1):11-23
14999484
Cardiovasc Intervent Radiol. 2007 Jul-Aug;30(4):675-87
17573553
Zhonghua Yi Xue Za Zhi. 2006 Mar 21;86(11):745-8
16681947
AJNR Am J Neuroradiol. 1997 Apr;18(4):639-45
9127024
J Neuroradiol. 1994 Apr;21(2):72-80
8014660
J Neurol Neurosurg Psychiatry. 2001 Jan;70(1):105-8
11118257
Neurol Med Chir (Tokyo). 2005 Dec;45(12):635-9
16377952
Stroke. 2000 Jun;31(6):1420-5
10835466
Stroke. 2005 Aug;36(8):1720-5
16002765
Neurology. 2004 Dec 28;63(12):2444-5
15623729
AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1807-11
15569752
J Pediatr Hematol Oncol. 2006 Mar;28(3):196-9
16679950
Stroke. 2008 May;39(5):1487-90
18340091
Stroke. 1999 Mar;30(3):489-94
10066841
Cerebrovasc Dis. 2003;15(1-2):17-21
12499706
AJNR Am J Neuroradiol. 2000 Jan;21(1):143-5
10669240
Stroke. 2004 Mar;35(3):664-70
14976332
J Stroke Cerebrovasc Dis. 2008 Mar-Apr;17(2):95-100
18346652
J Neurosurg. 2009 Mar;110(3):442-5
18834264
Neurosurg Clin N Am. 2000 Jan;11(1):49-65, viii
10565870
J Neurol. 2000 Apr;247(4):252-8
10836615
Lancet Neurol. 2007 Feb;6(2):162-70
17239803
Stroke. 2007 Feb;38(2):337-42
17204682